Gerard Evan

Last updated

Gerard Evan
Born (1955-08-17) 17 August 1955 (age 70) [1]
Alma mater St Peter's College, Oxford
King's College, Cambridge [1]
Known for Disease Models & Mechanisms
Awards Fellow of the Royal Society (2004)
FMedSci (1999) [2]
PhD (1982)
Scientific career
Fields Cancer [3] [4] [5] [6] [7] [8]
Disease biology
Myc regulator gene [9]
p53 tumour suppressor [10]
Institutions University of Oxford
University of Cambridge
UCSF [1] [11]
Cancer Research UK [12]
Ensemble Therapeutics
Thesis Monoclonal antibodies as reagents for the analysis of cell surfaces  (1982)
Website www.bioc.cam.ac.uk/uto/evan
labmed.ucsf.edu/about/faculty/pathology-gevan.html

Gerard Ian Evan FRS, FMedSci (born 17 August 1955) is a British biologist and, since May 2022, Professor of Cancer Biology at King's College London and a principal group leader in the Francis Crick Institute. Prior to this he was Sir William Dunn Professor of Biochemistry and Head of Biochemistry at the University of Cambridge (2009-2022). [11] [13]

Contents

Education

Evan was educated at St Peter's College, Oxford, where he studied Biochemistry, and King's College, Cambridge, where he was awarded his PhD in 1982 for research using Monoclonal antibodies. [1] [14]

Research

Evan does research to the determine the molecular basis of cancer. [15] [16] [17] [18] [19] [20] [21] [22]

Career

Prior to Cambridge, Evan was Royal Society Napier Professor at University College London and the Imperial Cancer Research Fund (1988-99), then Gerson & Barbara Bass Bakar Distinguished Professor of Cancer Biology, at University of California, San Francisco (1999-2011).

References

  1. 1 2 3 4 "EVAN, Prof. Gerard Ian". Who's Who 2013, A & C Black, an imprint of Bloomsbury Publishing plc, 2013; online edn, Oxford University Press.(subscription required)
  2. ↑ http://www.acmedsci.ac.uk/p59fid5303.html [ dead link ]
  3. ↑ Finch, A. J.; Soucek, L.; Junttila, M. R.; Swigart, L. B.; Evan, G. I. (2009). "Acute Overexpression of Myc in Intestinal Epithelium Recapitulates Some but Not All the Changes Elicited by Wnt/ -Catenin Pathway Activation". Molecular and Cellular Biology. 29 (19): 5306–5315. doi:10.1128/MCB.01745-08. PMC   2747972 . PMID   19635809.
  4. ↑ Garcia, D.; Warr, M. R.; Martins, C. P.; Brown Swigart, L.; Passegue, E.; Evan, G. I. (2011). "Validation of MdmX as a therapeutic target for reactivating p53 in tumors". Genes & Development. 25 (16): 1746–1757. doi:10.1101/gad.16722111. PMC   3165938 . PMID   21852537.
  5. ↑ Murphy, D. J.; Junttila, M. R.; Pouyet, L.; Karnezis, A.; Shchors, K.; Bui, D. A.; Brown-Swigart, L.; Johnson, L.; Evan, G. I. (2008). "Distinct Thresholds Govern Myc's Biological Output in Vivo". Cancer Cell. 14 (6): 447–457. doi:10.1016/j.ccr.2008.10.018. PMC   2723751 . PMID   19061836.
  6. ↑ Sodir, N. M.; Swigart, L. B.; Karnezis, A. N.; Hanahan, D.; Evan, G. I.; Soucek, L. (2011). "Endogenous Myc maintains the tumor microenvironment". Genes & Development. 25 (9): 907–916. doi:10.1101/gad.2038411. PMC   3084025 . PMID   21478273.
  7. ↑ Kain, K. (2008). "The future of cancer therapy: An interview with Gerard Evan". Disease Models and Mechanisms. 1 (2–3): 90–93. doi:10.1242/dmm.001396. PMC   2562192 . PMID   19048069.
  8. ↑ Anon (2008). "Making the paper: Gerard Evan". Nature. 455 (7213): xiii. doi: 10.1038/7213xiiia . S2CID   4410691.
  9. ↑ Evan, G. (2012). "Taking a Back Door to Target Myc". Science. 335 (6066): 293–294. Bibcode:2012Sci...335..293E. doi:10.1126/science.1217819. PMID   22267799. S2CID   26445434.
  10. ↑ Junttila, Melissa R.; Evan, Gerard I. (2009). "P53 — a Jack of all trades but master of none". Nature Reviews Cancer. 9 (11): 821–829. doi:10.1038/nrc2728. PMID   19776747. S2CID   29250930.
  11. 1 2 "UCSF Departments of Pathology and Laboratory Medicine | About | Faculty | Gerard I. Evan, PhD, FRS, FMedSci". Archived from the original on 1 June 2013.
  12. ↑ "Gerard Evan : Cancer Research UK". Archived from the original on 10 March 2014.
  13. ↑ Gerard Evan publications indexed by Microsoft Academic
  14. ↑ Evan, Gerard (1982). Monoclonal antibodies as reagents for the analysis of cell surfaces (PhD thesis). University of Cambridge.
  15. ↑ Christophorou, M. A.; Ringshausen, I.; Finch, A. J.; Swigart, L. B.; Evan, G. I. (2006). "The pathological response to DNA damage does not contribute to p53-mediated tumour suppression". Nature. 443 (7108): 214–217. Bibcode:2006Natur.443..214C. doi:10.1038/nature05077. PMID   16957739. S2CID   4417336.
  16. ↑ Junttila, M. R.; Karnezis, A. N.; Garcia, D.; Madriles, F.; Kortlever, R. M.; Rostker, F.; Brown Swigart, L.; Pham, D. M.; Seo, Y.; Evan, G. I.; Martins, C. P. (2010). "Selective activation of p53-mediated tumour suppression in high-grade tumours". Nature. 468 (7323): 567–571. Bibcode:2010Natur.468..567J. doi:10.1038/nature09526. PMC   3011233 . PMID   21107427.
  17. ↑ Soucek, L.; Whitfield, J.; Martins, C. P.; Finch, A. J.; Murphy, D. J.; Sodir, N. M.; Karnezis, A. N.; Swigart, L. B.; Nasi, S.; Evan, G. I. (2008). "Modelling Myc inhibition as a cancer therapy". Nature. 455 (7213): 679–683. Bibcode:2008Natur.455..679S. doi:10.1038/nature07260. PMC   4485609 . PMID   18716624.
  18. ↑ Evan, Gerard I.; Vousden, Karen H. (2001). "Proliferation, cell cycle and apoptosis in cancer". Nature. 411 (6835): 342–348. Bibcode:2001Natur.411..342E. doi:10.1038/35077213. PMID   11357141. S2CID   4414024.
  19. ↑ Hueber, A. O.; Zörnig, M.; Lyon, D.; Suda, T.; Nagata, S.; Evan, G. I. (1997). "Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis". Science. 278 (5341): 1305–1309. Bibcode:1997Sci...278.1305H. doi:10.1126/science.278.5341.1305. PMID   9360929.
  20. ↑ Chittenden, T.; Harrington, E. A.; O'Connor, R.; Remington, C.; Lutz, R. J.; Evan, G. I.; Guild, B. C. (1995). "Induction of apoptosis by the Bcl-2 homologue Bak". Nature. 374 (6524): 733–736. Bibcode:1995Natur.374..733C. doi:10.1038/374733a0. PMID   7715730. S2CID   4315947.
  21. ↑ Fanidi, A.; Harrington, E. A.; Evan, G. I. (1992). "Cooperative interaction between c-myc and bcl-2 proto-oncogenes". Nature. 359 (6395): 554–556. Bibcode:1992Natur.359..554F. doi:10.1038/359554a0. PMID   1406976. S2CID   4247014.
  22. ↑ Amati, B.; Dalton, S.; Brooks, M. W.; Littlewood, T. D.; Evan, G. I.; Land, H. (1992). "Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max". Nature. 359 (6394): 423–426. Bibcode:1992Natur.359..423A. doi:10.1038/359423a0. PMID   1406955. S2CID   4362486.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.